cyrilzakka/clinical-trials huggingface dataset:
Evaluation of the Effect of Novel Recruitment Maneuver Therapy for Postoperative Pulmonary Atelectasis

1. Oxygenation index and bedside ultrasound would be used to evaluate the therapeutic effect of novel recruitment maneuver therapy in the patients with pulmonary atelectasis after cardiac surgery.
2. To establish a new therapy strategy for pulmonary atelectasis after cardiac surgery and to evaluate its effectiveness and safety for the cardiac patients complicated with postoperative pulmonary atelectasis.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years
* Underwent cardiac surgery with CPB
* Patients with lung ultrasound evidence of atelectasis after surgery
* Agree to participate in this study by themselves or their family member.

Exclusion Criteria:

* Vasoactive-inotropic score (VIS)\>20
* Patients who were not suitable for using abdominal CPR compression-decompression instrument: bleeding from abdominal organs, abdominal aortic aneurysm, large abdominal tumor, intra-abdominal hypertension, etc
* Hemothorax or large pleural effusion confirmed by ultrasonography/X-ray
* Pneumothorax or air leak confirmed by ultrasonography/X-ray
* Considered by other researchers to be unsuitable for participation in this study
Elderly CAncer Patient

The management of older patients with cancer has become a major public health concern in Western countries because of the aging of the population and steady increase in cancer incidence with advancing age. Cancer treatment of aged patients is complex due to comorbidities, polypharmacy and functional status. The heterogeneity of the older population in terms of comorbidities and functional status may explain the difficulty in establishing management recommendations.

Study hypothesis is that a geriatric consultation using Geriatric Assessment (GA) can evaluate patient's resource and strengths, in order to help oncologist to define the most effective treatment. The GA developed by geriatricians and recommended by the International Society of Geriatric Oncology (SIOG), is a multidimensional assessment of general health status; comorbidities; functional status; nutritional, cognitive, psychological, and social parameters; and medications. The GA uses validated geriatric scales to produce an inventory of problems, which can then serve to develop an individualized geriatric intervention plan; it may be an important step in selecting elderly patients for cancer screening and treatment.

The objectives are:

* To assess the role of GA for decision making process for older patients with cancer
* To identify geriatric and oncologic factors associated with overall survival, treatment feasibility, toxicities, morbidities
* To develop and/or validate screening tests for frailty in geriatric oncology
* To develop and validate frailty classifications

Method: The ELCAPA (ELderly CAncer PAtient) survey is a French multicentric prospective study that includes all patients age 70 years or older who has a diagnosis of solid cancer or hematologic malignancies in French hospitals


Eligibility Criteria:
Inclusion Criteria:

* Patient aged 70 years or older
* Diagnosed cancer at all stage
* Referred to a geriatrician for GA
* Given oral non-opposition from patient or a legally mandated person

Exclusion Criteria:

* Oral opposition
Tongue Diagnosis in Chronic Kidney Disease

The Automatic Tongue Diagnosis System (ATDS) was developed to capture tongue images and extract features reliably to assist the diagnosis of traditional chinese medicine (TCM) practitioners.This project will employ the ATDS verified to extract the tongue features of patients with chronic kidney disease. A TCM indices derived through the non-intrusive tongue diagnosis procedure can provide valuable information for clinical doctors to analyze the current status of a patient and dynamically schedule a treatment plan, facilitating early detection and diagnosis of chronic kidney disease.

Chronic kidney disease (CKD) is a global financial and medical burden, because its high morbidity and mortality. Tongue diagnosis is an important diagnostic tool in traditional Chinese medicine. However, tongue diagnosis often biased by subjective judgements and environmental factors. The automatic tongue diagnosis system can noninvasively capture tongue images, automatically correct any lighting and color deviation and analyze tongue manifestations.

This protocol is a cross-sectional, case-controlled observational study investigating the tongue features of non-dialysis CKD and end-stage renal disease patients by using the noninvasive ATDS. CKD patients who meets inclusion and exclusion criteria will be enrolled. Participants will be divided into 3 groups according to their renal function and accept dialysis or not, including a non-dialysis CKD group, end stage renal disease (ESRD) group and control group. Tongue images will be captured and 9 tongue features including tongue shape, tongue color, fur thickness, fur color, saliva, tongue fissure, ecchymosis, tooth mark, and red dots will be extracted and analyzed by ATDS.

This protocol aims to apply noninvasive ATDS to analyze tongue features of CKD patients.

Eligibility Criteria:
Inclusion Criteria:

The patients will be included if they meet the following criteria:

1. age over 20 years old
2. The person who volunteered to participate this research and signed the agreement of institutional review board.

Exclusion Criteria:

1. Pregnant women
2. Patients with acute infection
3. The person who has cancer with brain metastasis and present with cognitive dysfunction such as dementia or delirium
4. unable to protrude the tongue stably
5. Patients with risk of temporomandibular joint dislocation
6. Those who did not sign the agreement of institutional review board
Measuring Normal and Impaired Walking in Children Using the GAITRite Walkway

Walking measurement in children is important but there are challenges associated with obtaining reliable repeatable data in a clinical setting that is meaningful and easy to interpret. This study set out to develop a new way to collect, record, and interpret walking data that is suitable for the clinical environment. Developmental percentile charts were selected as they are widely recognised and easily interpreted.

The primary output of the main cohort of typically developing children is the developmental percentile charts.

These will be then used to present the clinical longitudinal data against a normal backdrop of developmental changes in children.

This has multiple clinical applications in many of the children assessed by physiotherapy at GOSH and more widely Nationally and internationally

Eligibility Criteria:
Inclusion Criteria:

* Able to walk 100m

Exclusion Criteria:

* recent fracture or musculoskeletal injury which would affect gait
Topical Antimicrobial Effectiveness Testing

The primary objective of this study is to measure the antimicrobial effectiveness of ChloraPrep one-Step.


Eligibility Criteria:
Inclusion Criteria:

* in good general health
* have skin within 6 inches of the test sites that is free of tattoos, dermatoses, abrasions, cuts, lesions or other skin disorders.

Exclusion Criteria:

* topical or systemic antimicrobial exposure within 14 days prior to Screening Day
Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy

The goal of this study is to analyze the tumor microenvironment (TME) in gastric cancer patients treated with combined immunotherapy and chemotherapy. The main questions it aims to answer are:

* Provide profiles of TME between pre-treatment and post-treatment to gain insights into the mechanisms of immunotherapy combined with chemotherapy in advanced gastric cancer
* Investigate the crucial factors affecting treatment efficacy by comparing gastric cancer patients with varying treatment responses


Eligibility Criteria:
Inclusion Criteria:

* Non-bedridden, aged 18 to 70 years old;
* Eastern Cooperative Oncology Group (ECOG) score is 0 to 1;
* Histologically confirmed gastric adenocarcinoma with evaluable lesions based on RECIST 1.1;
* Advanced gastric cancer;
* Ready for receiving S-1 plus oxaliplatin chemotherapy and either nivolumab or sintilimab

Exclusion Criteria:

* History of other malignant diseases in the last 5 years;
* Prior chemotherapy, radiotherapy or immunotherapy;
* Not receiving S-1 plus oxaliplatin chemotherapy and either nivolumab or sintilimab.
Clinical Performance of CRE8 Drug Eluting Stent in All Comer Population

The aim of this study is to evaluate safety and efficacy performances of CRE8 Drug Eluting Stent, in patients comparable to the everyday's clinical practice population, with a specific focus on diabetics, that will be part of a pre-specified study subgroup.


Eligibility Criteria:
Inclusion Criteria:

* Age \> 18 years;
* Patients with symptoms of stable angina or documented silent ischemia;
* Patient with coronary artery disease ranging between 0 and 22 according to the Syntax score;
* Patients with acute coronary syndrome, including unstable angina, NSTEMI and STEMI;
* Patient is eligible for percutaneous coronary intervention (PCI) and is an acceptable candidate for surgical revascularization (CABG);
* Left ventricular ejection fraction \> 30%;
* Target de-novo lesions with diameter stenosis \> 50% (including total occlusion);
* Target lesion located in a target vessel with a diameter ranging from 2.5 to 4.0 mm;
* Patient has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Ethical Committee of the respective clinical site.

Exclusion Criteria:

* Female with childbearing potential or lactating;
* Known allergies to antiplatelets, anticoagulants, contrast media, sirolimus or cobalt chromium;
* Acute or chronic renal dysfunction (defined as creatinine greater than 2.5 mg/dl or on dialysis);
* Thrombocytopenia (platelet count less than 100,000/mm³) or hypercoagulable disorder;
* Known significant gastro-intestinal or urinary bleeding within the past 6 months;
* Patient refusing blood transfusion;
* Patient currently under immunosuppressant therapy;
* Patient with planned surgery within 6 months from the index procedure unless dual antiplatelet therapy is maintained throughout the peri-surgical period;
* Co-morbidities that could interfere with completion of study procedures, or life expectancy less than 1 year;
* Participating in another investigational drug or device trial that has not completed the primary endpoint or would interfere with the endpoints of this study;
* Patient underwent target vessel revascularization with a DES within 3 months prior to the index procedure;
* Target lesion is located or supplied by an arterial or venous bypass graft.
Contoura With Phorcides Compared to Wavefront Optimized LASIK

Comparing post-operative visual acuity and patient reported satisfaction between Contoura with Phorcides and WaveLight Wavefront Optimized.


Eligibility Criteria:
Inclusion Criteria:

* Patients at least age 21 years of age undergoing LASIK eye surgery
* Willing and able to comprehend informed consent and complete 1 month post-op visit
* Potential postoperative BCDVA of 20/20 or better in each eye based on Investigator's medical opinion
* Candidates for Contoura with Phorcides (Myopic, astigmatism \<3.0D)
* Both eyes targeted for plano
* Pre-operative total corneal Pachymetry 490um or above
* Stable refractive error \<0.50D change in preceding year
* Good general and ocular health
* Pre-operative exam completed within three months of surgery
* SCL discontinued 3 days prior to pre-op exam and the procedure
* Pachymetry above 490 with residual greater than 270um
* Candidates who, as determined by the investigator, can safely undergo LASIK

Exclusion Criteria:

* Patients under 21 years of age
* Concomitant ocular condition which would limit the BCVA at the discretion of the surgeon
* Patients with usual relative and absolute contraindications for LASIK surgery (Patients with severe dry eye, recurrent corneal erosion, uncontrolled Glaucoma, collagen vascular disorders, keratoconus or signs of keratoconus, uncontrolled Diabetes, Herpes)
* Pachymetry below 490
* Autoimmune or immunodeficiency diseases
* Pregnant or nursing women
* Patients with signs of inability to understand consent for study and procedure planned
* Patients with history of previous ocular surgery
* Patients with strabismus or amblyopia
* Patients that have a BCDVA of 20/25 or worse in either eye
Efficacy and Safety Study of Soluble Beta-1,3/1,6-glucan (SBG) Versus Placebo in Chronic Diabetic Foot Ulcers

Evaluation of efficacy and safety of SBG vs placebo in the treatment of chronic diabetic foot ulcers.

The objective of this study is to evaluate efficacy and safety of soluble beta-1,3/1,6-glucan (SBG) on chronic diabetic foot ulcers.

Eligibility Criteria:
Inclusion Criteria:

* Patients with chronic diabetic foot ulcer

Exclusion Criteria:

* Insufficient nutritional status, renal function or diabetes control
Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma

This study aims to evaluate the efficacy and safety of donafenib as adjuvant therapy for postoperative patients with high-risk recurrent Hepatocellular Carcinoma. This is a multicenter, randomized controlled study.


Eligibility Criteria:
Inclusion Criteria:

* Participants underwent radical resection of hepatocellular carcinoma 4 weeks before randomization
* High Risk of recurrence as assessed by tumor characteristics
* Without any anti-tumor therapy before surgery, except preoperative TACE therapy, traditional Chinese medicine therapy and interferon therapy
* Child-Pugh Class A statu
* ECOG Performance Status of 0 or 1
* CT/MR confirmed no recurrence or metastasis at ≥4 weeks after surgery
* Expected survival time of no less than 3 months

Exclusion Criteria:

* Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
* Evidence of residual or a history of spontaneous tumor rupture
* Recurrent HCC
* Prior received Liver transplantation
* Prior anti tumor therapy for treatment of HCC (including sorafenib or any other molecular therapy, anti-PD-1 antibody and other immunotherapies, FOLFOX systemic chemotherapy) is excluded
* AFP does not return to normal 4 weeks after operation
Fruits and Vegetables Incentives Study

The goal of this study is to evaluate the effectiveness of financial incentives delivered in real-time at point of purchase, on low-income consumers' purchase of fruits and vegetables, fruits and vegetables consumption, diet quality, and weight/BMI. The study will test real-time incentives compared to a no-incentive control condition.

To address diet quality disparities in low-income families, policy makers and health experts recommend strategies such as financial incentives to promote consumption of fruits and vegetables. Real-time incentives for purchasing fruits and vegetables are promising strategies to improve families' diets and health.

The aims of the study are:

1. To test the effects of financial incentives, delivered in real-time at the point of purchase, on low-income consumer purchases of fruits and vegetables
2. To evaluate the impact of real-time financial incentives compared to a control condition on FV consumption among adults and their children ,shopping habits, home food environments, diet quality, and weight/BMI
3. To adapt mobile platform technology to provide regular feedback to participants to motivate use of the incentive program to increase purchases and consumption of fruits and vegetables
4. To evaluate participant satisfaction with real-time healthy food choice incentives technology in both SNAP participants and income-eligible non-SNAP participants
5. To assess the acceptability and ease of use of real-time healthy food choice incentives technology among retails supermarket managers and staff in low-income neighborhoods.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older
* Speak English
* Do most of their food shopping at a participating supermarket
* Receive or are eligible to receive SNAP benefits
* Have a child in the household between the ages of 2-17
* Have a working smartphone
* Be the main household shopper

Exclusion Criteria:

* Participants will be excluded if the primary shopper and/or any children in the family have major medical or dental conditions that would prevent them from eating fruits and vegetables, or if they have a serious neurological disorder, dementia, or psychiatric condition that interferes with understanding study procedures
Effect of Synbiotic on Immune Response, Gut Permeability and Microbiota in Patient With Connective Tissue Disease

This is a double blind randomized placebo controlled trial to determine the effect of synbiotic to FOXP3 regulatory T cells, IL-17, gut permeability and gut microbiota in patients with connective tissue disease. Synbiotic can increase FOXP3 regulatory T cells, decrease IL-17 and improve gut permeability and gut microbiota in patients with connective tissue disease.

Study showed gut microbiota has a role in the pathogenesis of autoimmune diseases. Gut microbiota which can increase gut permeability affect the antigen presentation to the immune system. Synbiotic supplementation is expected to improve immune system, gut permeability, and gut microbiota in patients with connective tissue disease.

The subjects who fulfill inclusion criteria, willing to participate and sign informed consent will be randomized into two groups: the group receiving synbiotic containing probiotic (Lactobacillus helveticus R0052 60%, Bifidobacterium infantis R0033 20%, dan Bifidobacterium bifidum R0071 20%) and 80 mg fructooligosaccharide (group I, n=23) and the group receiving placebo (group II, n=23). Both groups receive intervention for two months. Patients continue to receive their immunosuppressive drugs (corticosteroids, hydroxychloroquine, mycophenolate mofetil, azathioprine, or cyclosporine).

Percentage of FOXP3 Regulatory T-cells, serum IL-17, zonulin, high sensitivity C-reactive protein, and gut microbiota are evaluated at the beginning and at the end of the study. FOXP3 regulatory T-cell is evaluated by flowcytometry. Serum IL-17 and zonulin are measured by ELISA. Gut microbiota is evaluated using 16s ribosomal RNA gene next generation sequencing. The DNA from the stool is isolated by DNA stool mini kit (QIAamp).

The results are presented in mean ± standard deviation, median (IQR 25-75%) and n (%). The Kolmogorov-Smirnov test is used to determine the normality of the data, assuming the normality of the data is fulfilled if p\> 0.05. Bivariate analysis uses paired T test if the data has normal distribution. If the distribution is not normal, Wilcoxon test will be used. Differences are said to be significant when the value of p \<0.05.

Eligibility Criteria:
Inclusion Criteria:

* patients diagnosed with connective tissue disease
* has gastrointestinal symptoms (abdominal pain, diarrhea, constipation, or bloating)
* age between 18-60 years old

Exclusion Criteria:

* pregnant or breastfeeding
* acute infection
* on antibiotic treatment
* taking yoghurt or probiotic supplementation in the last 3 weeks before recruitment
* taking corticosteroid more than 20 mg prednison a day or equal\\
* refuse to join the study
Evaluation of the Effects of Fluid Therapy on Respiratory Mechanics

The investigators hypothesize that large doses of fluids used during intraoperative could affect lung parenchyma structure and, consequently, gas exchange and respiratory mechanics. The purpose of this study is to evaluate fluids effects on oxygenation, respiratory mechanics, by using two different solutions: crystalloid or colloid.

Inclusion Criteria:

* patients undergoing elective abdominal, thoracic, vascular surgery
* minimum age 18 years
* informed consent

Exclusion Criteria:

* patients with severe cardiomyopathy or severe heart failure
* history of coagulation disorders
* patients with severe cardiovascular or respiratory disorders
* renal insufficiency

Respiratory mechanic parameters (i.e., inspiratory peak pressure, plateau pressure, total airway resistance, and static compliance) are obtained .Blood samples are drawn simultaneously from the arterial catheters for gas analysis. Data were collected after induction of anesthesia (T0) after 1 h (T1), 2 h (T2), 3 h (T3) and at the end of surgery.

Primary outcome: evaluate the fluids effects on oxygenation, respiratory mechanics

Secondary outcome: Incidence of surgery related complications

Eligibility Criteria:
Inclusion Criteria:

* patients undergoing elective abdominal, thoracic, vascular surgery
* minimum age 18 years
* informed consent

Exclusion Criteria:

* patients with severe cardiomyopathy or severe heart failure
* history of coagulation disorders
* patients with severe cardiovascular or respiratory disorders
* renal insufficiency
* severe liver diseases
Endobronchial Ultrasound Transbronchial Needle Aspiration Of Enlarged Mediastinal In Interstitial Lung Disease

The aim of this study is to assess the findings of mediastinal/hilar LN sampling by EBUS-TBNA in patients with non-sarcoidosis interstitial lung disease ( ILD) who demonstrate LN enlargement on chest imaging. Patients with non-sarcoidosis ILD referred for bronchoscopy will undergo LN sampling by EBUS-TBNA. Cytology results will be recorded along with clinico-radiologic features, BAL findings, histology and final ILD diagnosis.


Eligibility Criteria:
Inclusion Criteria:

1. non-sarcoidosis ILD (low probably of sarcoidosis based on radiology),
2. referred for bronchoscopy (BAL, TBLB or TBCB) in the Interventional Pulmonology Unit at Sheba Medical Center
3. Patients with LN enlargement ≥1 cm in short diameter at stations 2, 4, 7, 10 or 11 (LN stations accessible to EBUS-TBNA)

Exclusion Criteria:

1. known ILD
2. ILD with no indication to bronchoscopy
3. contraindication to bronchoscopy .
Ultrasound Guided Transversus Abdominis Plane(TAP) Block in Intensive Care Unit

The Transversus Abdominis Block (TAP) block is known to be an effective means of reducing patient pain after abdominal surgery. In the meantime, the general TAP block has been studied in patients who were in the recovery room and the ward after surgery. The purpose of this study was to determine the effect of pain reduction and opioid saving effects in patients with TAP block in ICU settings.

This study is a prospective study in a single institute of Seoul National University Bundang Hospital and is assigned to the test group and the control group by random assignment. In both groups, PCA (Patient Controlled Analgesia) was used as a post-operative pain control modality. In the Intervention group, a 0.25% Bupivacaine was used for transverse nerve block , and normal saline was used for placebo(control) group

The TAP block will be performed within 1 hour after entering the intensive care unit (ICU) in double blinded state

Eligibility Criteria:
Inclusion Criteria:

* Adults over 20 years of age
* Patients who entered the intensive care unit for monitoring and recovery after colonic resection through laparotomy
* Patients who voluntarily sign a written informed consent and know they have the right to withdraw their consent at any time.

Exclusion Criteria:

* Patients who are unconscious and require sedation below the Richmond Agitation Sedation Scale (-2) Patients who need continuous renal replacement therapy, cardiopulmonary bypass Patients with a history of allergic reactions to local anesthetics Patients resistant to narcotic analgesics (users of existing long-term narcotic analgesics) Patients who can not use self-analgesic treatment Patients who underwent surgery for organs other than abdomen and pelvis Patients with severe blood clotting disorders with a Prothrombin Time International normalized ratio of 2.0 or greater and Platelet less than 50,000